Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Case series:Danoprevir sodium tablets,/ritonavir oral
Sponsors
Huoshenshan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years old; 2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (Current Trial Version); 3. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration; 4. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration; 5. Patients who voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR>=30 times / min; or SaO2 / SpO2 =C, AST > 5 times upper limit); 4. Patients with contraindications specified in the instructions of danoprevir and ritonavir tablets; 5. Patients who plan to take protease inhibitors other than danoprevir and ritonavir simultaneously during the trial. 6. The pregnancy test of female subjects in the screening period was positive; 7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| novel coronavirus nucleic acid detection; | — |
Countries
China
Contacts
Public ContactJunxue Wang
Huoshenshan Hospital
Outcome results
None listed